Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma

References

• Cao H, Vergé V, Baron C, Martinache C, Leon A, Scholl S, et al. In vitro generation of dendritic cells from human blood monocytes of healthy donors and patients in experimental conditions compatible for their use in cell therapy. J Hematother Stem Cell Res 2000; 9: 183–194
   PubMedGoogle Scholar
• Garderet L, Cao H, Salamero J, Vergé V, Tisserand E, Scholl S, et al. In vitro production of dendritic cells from human blood monocytes for therapeutic use. J Hematother Stem Cell Res 2001; 10: 553–567
   PubMedGoogle Scholar
• Banchereau J, Steinman R M. Dendritic cells and the control of immunity. Nature 1998; 392: 245–252
   PubMed Web of Science ®Google Scholar
• Bataille R, Harousseau J. Multiple myeloma. N Engl J Med 1994; 330: 484–489
   PubMed Web of Science ®Google Scholar
• Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with haematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32
   PubMed Web of Science ®Google Scholar
• Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, et al. T-cell depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001; 98: 934–939
   PubMed Web of Science ®Google Scholar
• Segeren C M, Sonneveld P, Van der Holdt B, Vellenga E, Croockewit A J, Verhoef G E, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144–2151
   PubMed Web of Science ®Google Scholar
• Raje N, Anderson K. Thalidomide-a revival story. N Engl J Med 1999; 341: 1606–1609
   PubMed Web of Science ®Google Scholar
• Richardson P G, Schlossman R L, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulary drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067
   PubMed Web of Science ®Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
   PubMed Web of Science ®Google Scholar
• Stevenson F K, Anderson K C. Preparing the ground for vaccination against multiple myeloma. Immunology Today 2000; 21: 171
   Google Scholar
• Reichardt V L, Okada C Y, Liso A, Benike C J, Stockerl-Goldstein K E, Engleman E G, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 1999; 93: 2411–2419
   PubMed Web of Science ®Google Scholar
• Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999; 94: 673–683
   PubMed Web of Science ®Google Scholar
• Milazzo C, Reichardt V L, Muller M R, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003; 101: 977–982
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood 2003; 102: 1435–1442
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Nat Acad Sci USA 2002; 99: 13009–13013
   PubMed Web of Science ®Google Scholar
• Wen Y J, Min R, Tricot G, Barlogie B, Qing Y. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 2002; 99: 3280–3285
   PubMed Web of Science ®Google Scholar
• Lopez M, Fechtenbaum J, David B, Martinachc C, Chokri M, Canepa S, et al. Adoptive immunotherapy with activated macrophages grown in vitro from blood monocytes in cancer patients: a pilot study. J Immunother 1992; 11: 209–217
   PubMed Web of Science ®Google Scholar
• Kaiser A, Bercovici N, Abastado J P, Nardin A. Naïve CD8 T cells recruitment and proliferation are dependent on stage of dendritic cell maturation. Eur J Immunol 2003; 33: 162–171
   PubMed Web of Science ®Google Scholar
• Moreau-Aubry A, Le Guiner S, Labarriere N, Gesnel M C, Jotereau F, Breathnach R. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. J Exp Med 2000; 191: 1617–1624
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Jego G, Harousseau J -L, Vié H, Bataille R. Isolation of HLA-I-restricted cytotoxic T lymphocytes against autologous myeloma cells. Clin Cancer Res 1999; 5: 705–709
   PubMed Web of Science ®Google Scholar
• Yi Q, Osterborg A, Bergerbrant S, Mellstedt H, Holm G, Lefvert A K. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995; 86: 3043
   PubMed Web of Science ®Google Scholar
• Bogen B. Peripheral T-cell tolerance as tumor escape mechanism: deletion of CD4 + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma. Eur J Immunol 1996; 26: 2671–2679
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002; 100: 230–237
   PubMed Web of Science ®Google Scholar
• Zhou Y, Bosch M L, Salgaller M L. Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity. J Immunother 2002; 25: 289–303
   PubMed Web of Science ®Google Scholar
• King C A, Spellerberg M B, Zhu D, Rice J, Sahota S S, Thompsctt A R, et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998; 4: 1281–1286
   PubMed Web of Science ®Google Scholar
• Raje N, Hideshima T, Davies F E, Chauhan D, Treon S P, Young G, et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Hematol 2004; 125: 343–352
   PubMed Web of Science ®Google Scholar
• Hsu F J, Benike C, Fagnoni F, Liles T M, Czerwinski D, Taidi B, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52–58
   PubMed Web of Science ®Google Scholar
• Fiore F, Nuschak B, Peola S, Mariani S, Muraro M, Foglietta M, et al. Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favours the induction of Tr1-like regulatory T cells. Eur J Immunol 2005; 35: 1155–1163
   PubMed Web of Science ®Google Scholar
• Van baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999; 94: 1156–1164
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Mellerin M P, Labarrière N, Jego G, Moreau-Aubry A, Harousseau J L, et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol 2000; 30: 803–809
   PubMed Web of Science ®Google Scholar
• Milazzo C, Reichardt V L, Muller M R, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003; 101: 977–982
   PubMed Web of Science ®Google Scholar
• Orsini E, Bellucci R, Alyea E P, Schlossman R, Canning C, McLaughlin S, et al. Expansion of tumor-specific CD8 + T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res 2003; 63: 2561–2568
   PubMed Web of Science ®Google Scholar
• Osterborg A, Henriksson L, Mellstedt H. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma. Acta Oncologica 2000; 39: 797–800
   PubMed Web of Science ®Google Scholar
• Dhodapkar M V, Krasovsky J, Osman K, Geller M D. Vigorous premalignancy-specific effector T cell respons in the bone marrow of patients with monoclonal gammopathy. J Exp Med 2003; 198: 1753–1757
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck. Tumour-associated antigens in multiple myeloma. Br J Haematol 2003; 120: 3–9
   PubMed Web of Science ®Google Scholar
• De Angelis C, Drazen J M, Frizelle F A, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the international committee of medical journal editors. N Engl J Med 2004; 351: 1250–1251
   PubMed Web of Science ®Google Scholar
• Harrison S J, Cook G. Immunotherapy in multiple myeloma—possibility or probability?. Br J Haematol 2005; 130: 344–362
   PubMed Web of Science ®Google Scholar